A multicenter prospective study on efficacy and safety of imatinib generics: A report from Polish Adult Leukemia Group imatinib generics registry

American Journal of Hematology

Volumn 92, Issue 7, 2017, Pages E125-E128

  Sacha, Tomasz ^a   Góra Tybor, Joanna ^b   Szarejko, Monika ^c   Bober, Grażyna ^d   Grzybowska Izydorczyk, Olga ^e   Niesiobędzka Krężel, Joanna ^f   Dudziński, Marek ^g   Wasilewska, Ewa ^h   Myśliwiec, Krzysztof ⁱ   Gil, Justyna ^j   Gniot, Michał ^k   Pietkun, Iwona ^l   Mędraś, Ewa ^m   Hołojda, Jadwiga ⁿ   Wącław, Joanna ^a   Giannopoulos, Krzysztof ^o  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b INSTITUTE OF HEMATOLOGY AND TRANSFUSION MEDICINE   (Poland)

^c MEDICAL UNIVERSITY OF GDANSK   (Poland)

^d MEDICAL UNIVERSITY OF SILESIA   (Poland)

^e MEDICAL UNIVERSITY OF LODZ   (Poland)

^f MEDICAL UNIVERSITY OF WARSAW   (Poland)

^g Teaching Hospital No 1 in Rzeszow   (Poland)

^h MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

ⁱ University Hospital in Zielona Gora   (Poland)

^j Markiewicz Memorial Oncology Center Brzozow   (Poland)

^k POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^l Ludwik Rydygier Speciality Hospital in Krakow   (Poland)

^m Neoplastic Blood Disorders and Bone Marrow Transplantation in Wrocław ^*  (Poland)

ⁿ Specialized Hospital in Legnica   (Poland)

^o University of Lublin   (Poland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; GENERIC DRUG; IMATINIB; PROTEIN TYROSINE KINASE INHIBITOR;

ABDOMINAL PAIN; ADULT; AGED; ARTHRALGIA; BONE PAIN; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER REGISTRY; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG COST; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPEPSIA; EDEMA; EYELID EDEMA; FATIGUE; FEMALE; HEMATOLOGIC DISEASE; HUMAN; LETTER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE CRAMP; MYALGIA; NAUSEA; NEUTROPENIA; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RASH; SIDE EFFECT; SINGLE DRUG DOSE; SURVIVAL; THROMBOCYTOPENIA; TREATMENT FREE SURVIVAL; TREATMENT RESPONSE; VOMITING; CLINICAL TRIAL; MIDDLE AGED; POLAND;

ADULT; AGED; DRUGS, GENERIC; FEMALE; HUMANS; IMATINIB MESYLATE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; POLAND;

EID: 85019768656     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.24748     Document Type: Letter

References (6)

1. Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122(6):872–884. Aug 8doi: 10.1182/blood-2013-05-501569. Epub 2013 Jun 26.
2. Saavedra D, Vizcarra F. Deleterious effects of nonbranded versions of imatinib used for the treatment of patients with chronic myeloid leukemia in chronic phase: a case series on an escalating issue impacting patient safety. Leuk Lymphoma. 2014;55:2813–2816.
3. Sacha T. Molecular biology methods in the assessment of tyrosine kinase inhibitors therapy in patients with chronic myeloid leukemia. Habilitation dissertation. Medycyna Praktyczna. Kraków; 2012.
4. Hughes TP, Saglio G, Kantarjian HM, et al. Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. Blood. 2014;123(9):1353–1360.
5. Jabbour E, Kantarjian HM, Saglio G, et al. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2014;123(4):494–500.
6. Hoffmann VS, Baccarani M, Hasford J, et al. Treatment and outcome analysis of 2,904 patients from the EUTOS population based registry. Blood. 2015;126:2780.